The Challenges and Treatment of Sickle Cell Disease

A panel of experts considers the challenges of treating sickle cell disease and shares insight on emerging therapeutic agents.

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

Future Directions of Sickle Cell Disease Management
November 06, 2019 – 
Concluding their reflection on gene therapy, the panelists provide closing considerations for the future management of sickle cell disease.
Coverage of Older and Newer Therapies in Sickle Cell Disease
October 31, 2019 – 
Nuanced discussion on the coverage of older versus newer therapies available for the management of sickle cell disease.
Sickle Cell Disease: Cost and Access to Therapy in an Evolving Paradigm
October 31, 2019 – 
Given the evolving sickle cell disease treatment paradigm, the panel considers access to novel agents and the potential of specialty pharmacies.
Novel Biologic Therapies for Sickle Cell Disease Management
October 24, 2019 – 
Key opinion leaders shed light on novel therapies being investigated for sickle cell disease, including crizanlizumab, rivipansel, and ticagrelor.
Voxelotor's Potential as Treatment for Sickle Cell Disease
October 24, 2019 – 
Moving on to novel therapy for sickle cell disease, experts share insight on voxelotor, a once-daily oral agent with available phase 3 data.
Sickle Cell Disease: Challenges From the Payer Perspective
October 16, 2019 – 
The panelists consider remaining challenges in sickle cell disease as they relate to the payer’s role.
Sickle Cell Disease: Addressing Complications and Quality of Life
October 16, 2019 – 
A comprehensive discussion on sickle cell disease complication management that addresses disease severity and quality of life.
Integrating Nonpharmacologic Treatment Options for Sickle Cell Disease
October 09, 2019 – 
Experts review nonpharmacologic approaches to treating sickle cell disease, including blood transfusions and stem cell transplantation.
Sickle Cell Disease: Hydroxyurea or L-Glutamine Oral Powder
October 09, 2019 – 
Considerations for L-glutamine oral powder as a treatment option for sickle cell disease over the traditional hydroxyurea approach.
Hydroxyurea's Role in Managing Sickle Cell Disease
October 01, 2019 – 
Moving on to treatment strategies, the panel reviews hydroxyurea’s role as mainstay therapy for sickle cell disease.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.